Network Pharmacology and Component Analysis Integrated Study to Uncovers the Molecular Mechanisms of Lansium parasiticum Bark Extract in Colon Cancer Treatment
Article Sidebar
Abstract
Side effects and risk of resistance are common consequences of colon cancer treatment based on chemotherapy. The medicinal plant originating in Indonesia, Lansium parasiticum bark extract (LPBE), has not been studied much. The purpose of this study is to identify the compounds present in LPBE and explain how the molecular mechanisms of the composite inhibit colon cancer cells. LC-MS/MS Liquid Chromatography Tandem Mass Spectrophotometry has been used to identify compounds in LPBE. The ADMET program is used to determine absorption profiles and bioavailability per oral. The tissue pharmacology approach uses Cytoscape 3.9.1, GeneCards, Disgenet, STRING 2.0.0, SRplot, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway to predict the molecular anti-cancer mechanisms of these compounds. In vitro validation using PyRx Autodock Vina 9.0 and Biovia Discovery Studio with BAX (PDB ID:2YXJ), BCL2 (P DB ID:2W3L) and STAT3 receptors (PDB ID:6NJS). A total of 17 active compounds were identified through LC-MS/MS. The moronic acid compound showed the highest levels of 14.29% followed by 4-Morpholineacetic Acid 12.2% and ursolic aldehyde 8.37%. Pharmacological network analysis showed that the compounder works on the EGFR tyrosine kinase resistance path by targeting the BCL2, BAX, STAT3 genes. The results of the in silico validation support the results of tissue pharmacology findings. Ursolic aldehyde, and Moronic acid showed a higher affinity to the three receptors. Therefore, Lansium parasiticum bark extract (LPBE) is recommended for further study as a candidate anti-cancer drug both in vitro and in vivo.
References
Berger, S. I. and R. Iyengar (2009). Network Analyses in Systems Pharmacology. Bioinformatics, 25(19); 2466–2472
Campbell, K. J. and S. W. Tait (2018). Targeting BCL-2 Regulated Apoptosis in Cancer. Open Biology, 8(5); 180002
de Castro-Carpeño, J., C. Belda-Iniesta, E. C. Sáenz, E. H. Agudo, J. F. Batlle, and M. G. Barón (2008). EGFR and Colon Cancer: A Clinical View. Clinical and Translational Oncology, 10; 6–13
Dong, J., N.-N. Wang, Z.-J. Yao, L. Zhang, Y. Cheng, D. Ouyang, A.-P. Lu, and D.-S. Cao (2018). ADMETlab: A Platform for Systematic ADMET Evaluation Based on a Comprehensively Collected ADMET Database. Journal of Cheminformatics, 10; 1–11
Douaiher, J., A. Ravipati, B. Grams, S. Chowdhury, O. Alatise, and C. Are (2017). Colorectal Cance —Global Burden, Trends, and Geographical Variations. Journal of Surgical Oncology, 115(5); 619–630
Fadhilah, K., S. Wahyuono, and P. Astuti (2021). Fractions and Isolated Compounds from Lansium Domesticum Fruit Peel Exhibited Cytotoxic Activity against T-47D and HepG2 Cell Lines. Biodiversitas Journal of Biological Diversity, 22(9); 3743–3748
Goel, V., P. Kaur, L. D. Singla, and D. Choudhury (2020). Biomedical Evaluation of Lansium Parasiticum Extract Protected Silver Nanoparticles against Haemonchus Contortus, a Parasitic Worm. Frontiers in Molecular Biosciences, 7; 595646
Ionescu, V. A., G. Gheorghe, N. Bacalbasa, A. L. Chiotoroiu, and C. Diaconu (2023). Colorectal Cancer: From Risk Factors to Oncogenesis. Medicina, 59(9); 1646
Jiang, L., J. Lu, Y. Qin, W. Jiang, and Y. Wang (2020). Anti-tumor Effect of Guava Leaves on Lung Cancer: A Network Pharmacology Study. Arabian Journal of Chemistry, 13(11); 7773–7797
Khodapasand, E., N. Jafarzadeh, F. Farrokhi, B. Kamalidehghan, and M. Houshmand (2015). Is Bax/Bcl-2 Ratio Considered As a Prognostic Marker with Age and Tumor Location in Colorectal Cancer? Iranian Biomedical Journal, 19(2); 69
Kuipers, E., W. Grady, D. Lieberman, T. Seufferlein, J. Sung, P. Boelens, C. van de Velde, and T. Watanabe (2015). Colorectal Cancer. Nature Reviews. Disease Primers., 1; 15065
Laurent-Puig, P., A. Cayre, G. Manceau, E. Buc, J.-B. Bachet, T. Lecomte, P. Rougier, A. Lievre, B. Landi, and V. Boige (2009). Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit from Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer. Journal of Clinical Oncology, 27(35); 5924–5930
Liu, F., T. Zhang, S. Zou, B. Jiang, and D. Hua (2015). B7-H3 Promotes Cell Migration and Invasion through the Jak2/Stat3/MMP9 Signaling Pathway in Colorectal Cancer. Molecular Medicine Reports, 12(4); 5455–5460
Liu, X., J. Wu, D. Zhang, K. Wang, X. Duan, and X. Zhang (2018). A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. On Colorectal Cancer. Evidence-Based Complementary and Alternative Medicine, 2018; e6517034
Lubis, M. F., H. Syahputra, D. N. Illian, and V. E. Kaban (2022). Antioxidant Activity and Nephroprotective Effect of Lansium parasiticum Leaves in Doxorubicin-Induced Rats. Journal of Research in Pharmacy, 26; 565–573
Ma, J.-h., L. Qin, and X. Li (2020). Role of STAT3 Signaling Pathway in Breast Cancer. Cell Communication and Signaling, 18; 1–13
Mutiah, R., W. S. Bhagawan, B. Ma’arif, and J. M. S. Rahmandika (2019a). Metabolite Fingerprinting Eleutherine palmifolia (L.) Merr. Using UPLC-QTOF-MS/MS. Majalah Obat Tradisional, 24(3); 139–159
Mutiah, R., M. F. Hariz, Y. Y. A. Indrawijaya, and B. Ma’arif (2019b). In Silico Prediction of Isoliquiritigenin and Oxyresveratrol Compounds to BCL-2 dan VEGF-2 Receptors. Indonesian Journal of Cancer Chemoprevention, 10(2); 51–59
Patil, V. S., S. H. Deshpande, D. R. Harish, A. S. Patil, R. Virge, S. Nandy, and S. Roy (2020). Gene Set Enrichment Analysis, Network Pharmacology and in Silico Docking Approach to Understand the Molecular Mechanism of Traditional Medicines for the Treatment of Diabetes Mellitus. Journal of Proteins and Proteomics, 11(4); 297–310
Potipiranun, T., W. Worawalai, and P. Phuwapraisirisan (2018). Lamesticumin G, a New ???? Glucosidase Inhibitor from the Fruit Peels of Lansium Parasiticum. Natural Product Research, 32(16); 1881–1886
Radha, G. and S. C. Raghavan (2017). BCL2: A Promising Cancer Therapeutic Target. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1868(1); 309–314
Rego, R., N. Foster, T. Smyrk, M. Le, M. O’connell, D. Sargent, H. Windschitl, and F. Sinicrope (2010). Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. British journal of cancer, 102(1); 165–172
Sawicki, T., M. Ruszkowska, A. Danielewicz, E. Niedźwiedzka, T. Arłukowicz, and K. E. Przybyłowicz (2021). A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers, 13(9); 2025
Siddiqui, A. D. and B. Piperdi (2010). KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy. Annals of Surgical Oncology, 17(4); 1168–1176
Vega, P., F. Valentin, and J. Cubiella (2015). Colorectal Cancer Diagnosis: Pitfalls and Opportunities. World Journal of Gastrointestinal Oncology, 7(12); 422
Xi, Y. and P. Xu (2021). Global Colorectal Cancer Burden in 2020 and Projections to 2040. Translational Oncology, 14(10); 101174
Yang, X., Y. Tao, R. Xu, W. Luo, T. Lin, F. Zhou, L. Tang, L. He, and Y. He (2023). Analysis of Active Components and Molecular Mechanism of Action of Rubia cordifolia L. In the Treatment of Nasopharyngeal Carcinoma Based on Network Pharmacology and Experimental Verification. Heliyon, 9; e17078
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.